About the Program
The Neuro-Oncology Fellowship program provides intense, comprehensive training in the management of primary brain tumors and neurological complications of cancer. The overall goal is to cultivate the careers of young physician-scientists to become leaders in the field of neuro-oncology. The fellowship program is carefully, but flexibly designed to accommodate the individual needs of candidates aiming at either clinical practice or academic positions upon completion of training.
The Neuro-Oncology Fellowship consists of two to three years of training:
- The first year is dedicated to clinical neuro-oncology, dealing with primary brain tumors in outpatient and inpatient settings and with neurological complications of cancer.
- The second year adds opportunities for clinical or basic research coupled with more independent patient care management.
- An optional third year provides protected research time for fellows to develop and enhance their individual interests, with mentoring by experienced basic and clinical research faculty.
The Neuro-Oncology Fellowship Program at MD Anderson provides a unique experience for trainees. For fellows interested in entering clinical practice, we offer rotations through pain and palliative care. This is a niche that is important to neurology and oncology groups interested in expanding the repertoire of clinical practice.
The fellows also have a distinctive opportunity to participate in our clinical research activities to gain experience in clinical trial design and execution, drug development, regulatory aspects of trials and development of strategies that hold promise in brain tumor therapy. In addition, our fellows learn the intricacies of how a multidisciplinary, expert team works efficiently to translate research into clinical practice to provide optimal care for patients.
Furthermore, the Neuro-Oncology Fellowship Program stands out by offering:
- Financial support for trainees to attend conferences of their choosing
- Regular lectures and advanced education opportunities throughout the institution
- Opportunity to train with a dynamic, multidisciplinary team at the No. 1 hospital for cancer care in the nation, per U.S. News & World Report’s “Best Hospitals” survey
- UCNS certification eligibility for neuro-oncology upon completion of the program
Fellows must hold an M.D. or D.O. degree, have completed a residency in neurology or neurosurgery and, if applicable, have an active ECFMG certification.
MD Anderson offers a smoke-free environment and is an Equal Opportunity/ Affirmative Action Employer.
Apply to this program using the DISCOVER online application system. Now accepting applications for the 2018-2019 fellowship.
Final selection of applicants will be based on the requirements above, in addition to evaluation of prior academic background and formal interviews. Interested candidates may submit a current CV and three letters of reference to:
John F. de Groot, M.D.
Fellowship Program Director
Neuro-Oncology, Unit 431
The University of Texas MD Anderson Cancer Center
P.O. Box 301402
Houston, Texas 77230-1402
The Brain and Spine Center provides multidisciplinary clinic facilities for neuro-oncology, neurosurgery and radiation oncology, supported by neuropathology and neuro-radiology. The center has active interactions with the Sections of Pediatric Neuro-Oncology, Palliative Care and Symptom Management, Anesthesia Pain Service, Neuropsychology and Social Work.
Chemotherapy is typically administered in a centralized Ambulatory Treatment Center, which provides expert care and monitoring in bed and chair units. For some Phase I or II studies that require time-sensitive pharmacokinetic studies, the Clinical-Translational Research Center provides full phlebotomy and laboratory services as well as outstanding nursing care.
Neuro-Oncology and Neurosurgery inpatients are cared for on a 32-bed neuro inpatient unit, but neurology consultations may be required in any of the other units of this 512-bed hospital.
The neuro-oncology fellow will benefit from:
- The large number of primary brain tumor patients (over 500 new patients annually), providing unparalleled opportunity for intensive and diverse experience in clinical care issues
- Elective one- to two-month rotations with pain and palliative care, pediatric neuro-oncology, radiation therapy and other oncologic subspecialties, if the fellow is interested in broadening his/her experience in such related fields
- Exposure to a rich variety of consultative neuro-oncology referrals, including patients undergoing treatment with novel investigational agents
- Exposure to a variety of clinical research protocols for primary and secondary neurological malignancies
The wealth of patient referrals also provides a unique opportunity to conduct basic research and correlative studies on incidental samples of tissue or blood, which are routinely banked for this purpose.
MD Anderson offers many opportunities to interact and collaborate with a diverse group of experts in basic research, as well as access to cutting-edge technology including genomic and proteonomic facilities, resources in multiple areas of cancer biology including apoptosis, invasion, angiogenesis, developmental sciences, DNA repair, animal models and gene discovery.
The Brain Tumor Research Program laboratories are organized by research focus, not departmental boundaries, and are consolidated in 10,000 square feet located on a single floor in the Mitchell Basic Sciences Research Building. Departmental and institutional research support funds and equipment have been pooled to provide a common group-wide resource that promotes close multidisciplinary interaction and support among members.
In addition to fellowship-specific educational opportunities:
- The Brain Tumor Research Program hosts a bi-weekly seminar series, featuring nationally and internationally respected speakers on issues related to CNS tumors.
Fellows are also encouraged to attend other of the many lectures available around the institution that may be relevant to their training experience.
- Weekly CNS Tumor Board sessions offer valuable educational experience, as each of the disciplines provide input regarding pathologic and radiologic findings, disease and treatment history, and discuss options for future treatment.
- Protocol meetings review accruals, responses and toxicities for each open clinical trial, and provide a forum to discuss new treatment strategies and protocol design.
- Frequent laboratory group meetings of ongoing research optimize the basic and translational research experience.
David Blas-Boria (2010-2011), VA Caribbean Healthcare System, Puerto Rico
Brett Theeler (2010-2012), Walter Reed Medical Center, Bethesda, MD
Michael Pearlman (2010-2012), Blue Sky Neurology, Englewood, CO
Zsila Sadighi (2010-2012), St. Jude Children's Research Hospital, Memphis, TN
Mark D. Anderson (2011-2013), University of Mississippi Medical Center, Jackson, MS
Pedro Garciarena (2011-2013), Physician Regional Healthcare System, Naples, FL
Mohamed Hamza (2011-2013), Ohiohealth Neurological Physicians, Columbus, OH
Shlomit Yust-Katz (2011-2013)
Barbara O'Brien (2012-2014), MD Anderson, Houston, TX
Jacob Mandel (2012-2014), Baylor College of Medicine, Houston, TX
David Cachia (2013-2015), Medical University of South Carolina, Charleston, SC
Carlos Kamiya-Matsuoka (2013-2015), MD Anderson, Houston, TX
Shiao-Pei Weathers (2013-2014), MD Anderson, Houston, TX
Na Tosha Gatson (2014-2016), Geisinger Health System, Danville, PA
Clement Pillainayagam (2014-2016), Rush University Medical Center, Chicago, IL
Randi Baculi (2000-2002), North Texas Neurological, Mesquite, TX and Rowlett, TX
Howard Colman (2001-2002), University of Utah, Salt Lake City, UT
Pierre Giglio (2001–2003), Medical University of South Carolina, Charleston, SC
Ivo W Tremont (2001–2003) Houston Methodist, Houston, TX
Sudhakar Tummala (2001-2002), MD Anderson, Houston, TX
John de Groot (2002-2004), MD Anderson, Houston, TX
Jonathan Grunfeld (2002-2004), Tel Aviv University, Tel Aviv, Israel
Yvonne Kew (2002-2004), Houston Methodist Hospital Research Institute, Houston, TX
Siew Ju See (2002–2004), National Neuroscience Institute, Singapore
Monica Loghin (2003-2005), MD Anderson, Houston, TX
Kristin Gabriel (2004–2005), The Vancouver Clinic, Vancouver, WA
Javier Gonzalez (2004–2006), West Virginia University, Morgantown, WV
Marta Penas-Prado (2005-2007), MD Anderson, Houston, TX
Slobodan Miric (2005-2006), Dr. Miric Neurology, Denville, NJ
Jai Grewal (2005–2007), Neurological Surgery Group, Long Island, NY
Caryl Dellinger (2006-2007), Marshfield Clinic, Marshfield, WI
Merja Kallio (2006-2007), University of Oulu, Department of Paediatrics
Ray Bogitch (2007-2008), Seton Brain and Spine Institute, Austin, TX
Brian Vaillant (2007-2010), Seton Brain and Spine Institute, Austin, TX
Stan Han (2008-2009), UAB School of Medicine, Birmingham, AL
Shirley Ong (2008-2010), UAMS College of Medicine, Little Rock, AK
Jing Wu (2008-2010), Center for Cancer Research, National Cancer Institute, Bethesda, MD
Tobias Walbert (2008-2010), Henry Ford Hospital, Detroit, MI
Nicole Shonka (2009-2010), University of Nebraska Medical Center, Omaha, NE
Aaron Mammoser (2009-2011), University of Michigan Health System, Ann Arbor, MI
Isaac Melguizo-Gavilanes (2009-2011), Neuro-Oncology Associates at Baylor Charles A. Sammons, Cancer Center, Dallas, TX
Mark Alan Simaga (1990-1991), St. Mary Medical Center, Hobart, IN
Todd Jeffry Janus (1991-1992), Iowa Methodist Medical Center, Des Moines, IA
Adrian Galan (1991-1992)
Athanassios P. Kyritsis (1991-1992), University of Ioannina School of Medicine, Ioannina, Greece
Elizabeth Strauch (1991-1992), Houston Hospice, Houston, TX
Alexandra Flowers (1991-1993), Hartford Hospital, Hartford, CT
Jennifer Daniels (1992-1994)
Qaiser Yusuf (1992-1994), Neurology and Pain Clinic, Baytown, TX
Charles Conrad (1992-1994)
Vladan Milosavljevic (1993-1995), New England Neurological Associates, P.C., Lawrence, MA
Paolo Manfredi (1993-1994), Memorial Sloan-Kettering Cancer Center, Pain and Palliative Care, New York, NY
Samer Kaba (1994-1996), Vice President, Osmotica Pharmaceutical Corp., Marietta, GA
Wolley Oladut (1994-1995), South Texas Pain Management, Richmond, TX
Eric Wong (1995-1997), Beth Israel Deaconess Medical Center, Boston, MA
Masood Hashmi (1995-1997), Space Coast Neurology, Okeechobee, FL
Christopher Watling (1995-1996), London Regional Cancer Centre, London, ON, Canada
Vinaykumar Puduvalli (1996-1998), Ohio State University Comprehensive Cancer Center, Columbus, OH
Morris Groves (1996-1998), Texas Oncology, Austin, TX
Joon Uhm (1997-1999), Mayo Clinic, Rochester, MN
John Rossi (1997-2000), St. Luke's The Woodlands Hospital, The Woodlands, TX
Lara Kunschner Ronan (1998-2000), Dartmouth-Hitchcock Medical Center, Lenanon, NH
Sigmund Hsu (1999-2002), The University of Texas Health Science Center at Houston, Houston, TX
George Bobustuc (1999-2001), Aurora Cancer Care, Milwaukee, WI
Minsoo Kang (1999–2001), Comprehensive Clinical Services Healthcare, Williamsville, NY
Karen Jurgensen (1982-1983), Plaza Medical Center of Fort Worth, Fort Worth, TX
Te-Long Hwang (1983-1984), University of South Carolina, Columbia, SC
Jorge Martinez (1983-1984), Metropolitan Methodist Hospital, San Antonio, TX
Kinzo Iwata (1984-1985), Aichi University, Aichi Prefecture, Japan
Agustino Castellanos (1984-1986), NeuroCare Consultants, Palm Beach Gardens, FL
Pamela New (1985-1987), Baylor College of Medicine, Houston, TX
Keith Privett (1987-1988)
Bernard L. Maria (1986-1988), Medical University of South Carolina, Charleston, SC
Lesley Newton (1986-1987)
Sanjeev K. Deveshwar (1988-1989), Greensboro Radiology Associates, Greensboro, NC
Laszlo L. Mechtler (1988-1989), Dent Neurological Institute, Buffalo, NY
Everton Edmondson (1989-1990), Private Practice, Houston, TX
Maria Carvajal-Gandia (1989-1990)
MD Anderson Cancer Center is committed to encouraging good health and staying true to our mission to end cancer. If you are applying for a GME fellowship or residency program starting on or after July 1, 2016, please be advised that MD Anderson will have instituted a tobacco-free hiring process as part of its efforts to achieve these goals. If you are offered an appointment, you will be subject to a Pre-Employment Drug Screen for tobacco compounds in compliance with applicable state laws. If you do not pass the urine drug screening which includes testing for tobacco compounds, you CANNOT be appointed at MD Anderson. Should you fail to meet this contingency, MD Anderson will withdraw your offer of appointment for the academic year. You may reapply for the following academic year, but there are no guarantees that you will be offered a position as many of our programs are already filled for several years out.